Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659020 · ClinicalTrials.gov registry record · Phase 1
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
A Phase 1 study of Soft Tissue Sarcoma, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT02659020 is a Phase 1 study of Soft Tissue Sarcoma that has completed, run by Eli Lilly and Company. The registered enrollment target is 310 participants, above the 73-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (325% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT02659020, a Phase 1 study of Soft Tissue Sarcoma, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Gemcitabine
- DRUG Olaratumab
Study Locations (20)
New York
- Monter Cancer Center - Lake Success
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- Mayo Clinic-Jacksonville - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
Texas
- University of Texas Southwestern Medical Center at Dallas - Dallas
- University of Texas MD Anderson Cancer Center - Houston
California
- UCLA Medical Center - Santa Monica
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- Georgia Cancer Specialists PC - Atlanta
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659020
The ClinicalTrials.gov registry entry for NCT02659020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (325% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02659020 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT02659020 about?
NCT02659020 is a clinical study titled "A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma". The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
What is the current status of trial NCT02659020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2016-03-01. Estimated completion is 2021-04-27.
What conditions does trial NCT02659020 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT02659020?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Olaratumab (DRUG).
Who is sponsoring clinical trial NCT02659020?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02659020 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
-
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
RECRUITING · Phase 1
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.